Table 3 A Brief Summary of Responses to EGFR-TKI Treatment in cavitary and noncavitary adenocarcinoma patients with EGFR mutations
Characteristic | Cavity N = 15 | Noncavity N = 261 | P |
|---|---|---|---|
Response, no. (%) | |||
 CR | 0 (0.0) | 0 (0.0) |  |
 PR | 8 (53.3) | 154 (59.0) |  |
 SD | 6 (40.0) | 86 (33.0) |  |
 PD | 1 (6.7) | 21 (8.0) |  |
mPFS (95%CI), mo | |||
 Overall cohort | 6.5 (5.3–7.7) | 11.0 (9.3–12.7) | 0.006 |
 Exon 19 deletion | 9.7 (2.1–17.3) | 10.4 (9.0–11.8) | 0.483 |
 L858R mutation | 4.2 (2.5–5.9) | 11.0 (7.6–14.4) | < 0.001 |
ORR, % | |||
 Overall cohort | 53.3 | 59.0 | 0.664 |
 Exon 19 deletion | 55.6 | 61.1 | 0.737 |
 L858R mutation | 50.0 | 54.8 | 1.000 |
DCR, % | |||
 Overall cohort | 93.3 | 92.0 | 1.000 |
 Exon 19 deletion | 100.0 | 90.7 | 1.000 |
 L858R mutation | 83.3 | 92.7 | 0.387 |